A Phase 1, Randomized, Double-Blind, Cross-Over, Placebo- and Active-Controlled Cardiac Safety Study of Therapeutic and Supratherapeutic Doses of Fumaryl Diketopiperazine Administered as Technosphere® Inhalation Powder in Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Double-Blind, Cross-Over, Placebo- and Active-Controlled Cardiac Safety Study of Therapeutic and Supratherapeutic Doses of Fumaryl Diketopiperazine Administered as Technosphere® Inhalation Powder in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2012

At a glance

  • Drugs Insulin; Moxifloxacin
  • Indications Bacterial infections; Diabetes mellitus
  • Focus Adverse reactions
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 29 Jun 2011 Results will be presented at ADA-2011 according to a MannKind Corporation media release. Results were also summarised in the media release.
    • 29 Jun 2011 New trial record
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top